This is a bit all or nothing. If it is a yes then who knows could be a fair jump at lea ssd t back to 1.30. If it is a no that throws the entire program into question as if we cant get approval for skin application then surely no chance for iv. That being said I guess that sepsis was always our target and all clinical data to date from the company has been towards getting the sepsis trial go ahead. The skin application seems to have been a bit of a side application that came up due to request by a teaching hospital as it seems they saw a potential application. Maybe we dont have sufficient data to support that request? Would be frustrating if that is the case as it would certainly reflect on sepsis side of things.
RCE Price at posting:
$1.06 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)